Real-World Safety of First-Line Therapies for la/mUC in the US

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Amanda Nizam, MD, of Cleveland Clinic, touched on her study of real-world safety of first-line therapies for locally advanced or metastatic urothelial cancer in the United States.

Dr. Nizam spoke to key trends or patterns observed, as well as how her findings figure to inform clinical decision-making when selecting first-line therapies.